Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW A ENGELBRECHT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1861406134
CMS profile
129972
Location
ASHEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,927.92

166 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,901.56 165
Education $26.36 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $472.11 66
UCB, Inc. $161.09 5
Alexion Pharmaceuticals, Inc. $136.07 6
Teva Pharmaceuticals USA, Inc. $127.66 6
TG Therapeutics, Inc. $117.13 4
Biogen, Inc. $96.16 5
PFIZER INC. $91.86 4
ACADIA Pharmaceuticals Inc $86.67 3
Neurelis, Inc. $85.49 2
MDD US Operations, LLC $70.36 3
Cycle Pharmaceuticals Inc $67.49 3
Merz Pharmaceuticals, LLC $62.47 3
Vanda Pharmaceuticals Inc. $61.86 3
JAZZ PHARMACEUTICALS INC. $58.86 2
Neurocrine BioSciences, Inc. $56.36 2
SK Life Science, Inc. $55.93 2
Lundbeck LLC $53.65 2
Ipsen Biopharmaceuticals, Inc $53.16 2
Takeda Pharmaceuticals U.S.A., Inc. $53.00 2
ARGENX US, INC. $51.85 2
Celgene Corporation $51.43 2
Mallinckrodt Hospital Products Inc. $49.69 2
Eisai Inc. $48.44 2
Amgen Inc. $47.50 2
Janssen Biotech, Inc. $47.31 2
Axsome Therapeutics, Inc. $46.85 2
Averitas Pharma Inc. $46.03 2
Impel Pharmaceuticals LLC $45.62 2
Amneal Pharmaceuticals LLC $45.01 2
CATALYST PHARMACEUTICALS, INC. $44.73 2
Xeris Pharmaceuticals, Inc. $40.24 1
AstraZeneca Pharmaceuticals LP $37.80 2
REVANCE THERAPEUTICS, INC. $33.05 1
Ultragenyx Pharmaceutical Inc. $28.32 1
C2N Diagnostics, LLC $27.78 1
Genentech USA, Inc. $27.49 1
Otsuka America Pharmaceutical, Inc. $26.46 1
CSL Behring $24.35 1
GE HEALTHCARE $23.72 1
Globus Medical, Inc. $23.51 1
Lilly USA, LLC $22.18 1
Novartis Pharmaceuticals Corporation $20.61 1
Abbott Laboratories $19.18 1
GENZYME CORPORATION $17.90 1
Tonix Medicines, Inc. $17.62 1
EMD Serono, Inc. $16.10 1
InSightec,Inc $15.50 1
Medtronic, Inc. $14.27 1

Page 2 of 4; records 51–100 of 166 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW A ENGELBRECHT

NPI 1861406134 · CMS profile ID 129972

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ASHEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 166 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861406134?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 166 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861406134?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 166 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861406134?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 166 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1861406134?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

166 matching records · $2,927.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 166 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 166.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $20.1109/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819431 CMS
Amneal Pharmaceuticals LLC $23.2709/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220532803 CMS
TG Therapeutics, Inc. $24.1809/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226217952 CMS
Globus Medical, Inc. $23.5109/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250110563 CMS
ABBVIE INC. $5.6609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819429 CMS
ARGENX US, INC. $17.6409/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240449494 CMS
Mallinckrodt Hospital Products Inc. $26.3608/27/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1211963530 CMS
Teva Pharmaceuticals USA, Inc. $28.7808/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247383163 CMS
Teva Pharmaceuticals USA, Inc. $19.5508/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247383161 CMS
GE HEALTHCARE $23.7208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244292217 CMS
ABBVIE INC. $4.7508/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819427 CMS
Alexion Pharmaceuticals, Inc. $26.9808/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202950672 CMS
JAZZ PHARMACEUTICALS INC. $30.2608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234322079 CMS
ABBVIE INC. $5.5008/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819423 CMS
ABBVIE INC. $16.6208/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819425 CMS
ABBVIE INC. $3.8108/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819419 CMS
ABBVIE INC. $2.1208/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819421 CMS
C2N Diagnostics, LLC $27.7808/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244141072 CMS
Xeris Pharmaceuticals, Inc. $40.2408/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250167812 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.3207/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223909621 CMS
ABBVIE INC. $4.2907/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819415 CMS
ABBVIE INC. $2.0807/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819417 CMS
UCB, Inc. $26.7207/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224606797 CMS
ACADIA Pharmaceuticals Inc $21.6607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247772090 CMS
ABBVIE INC. $3.2707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819411 CMS
ABBVIE INC. $2.8107/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819413 CMS
Vanda Pharmaceuticals Inc. $21.6607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232961858 CMS
Janssen Biotech, Inc. $21.1807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175045930 CMS
Impel Pharmaceuticals LLC $22.8107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211448621 CMS
Impel Pharmaceuticals LLC $22.8107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211448651 CMS
ABBVIE INC. $4.1707/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819407 CMS
ABBVIE INC. $1.8507/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819409 CMS
Axsome Therapeutics, Inc. $24.5807/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235400186 CMS
CATALYST PHARMACEUTICALS, INC. $22.4507/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253225277 CMS
ABBVIE INC. $5.7006/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819405 CMS
Mallinckrodt Hospital Products Inc. $23.3306/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211963528 CMS
ABBVIE INC. $4.5806/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819403 CMS
ABBVIE INC. $4.1906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819401 CMS
Neurocrine BioSciences, Inc. $28.1806/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242992705 CMS
Medtronic, Inc. $14.2706/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219082398 CMS
PFIZER INC. $27.5906/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231613018 CMS
Merz Pharmaceuticals, LLC $18.8906/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232564245 CMS
ABBVIE INC. $8.3806/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819399 CMS
Biogen, Inc. $23.5006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208433848 CMS
Amgen Inc. $28.8606/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228506444 CMS
AstraZeneca Pharmaceuticals LP $18.6005/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206617896 CMS
MDD US Operations, LLC $24.1705/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241847460 CMS
ABBVIE INC. $2.2905/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819395 CMS
ABBVIE INC. $4.3305/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201819397 CMS
Janssen Biotech, Inc. $26.1305/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175044486 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,734.60 159
PY2020 $877.94 51
PY2021 $2,048.48 124
PY2022 $2,316.99 123
PY2023 $2,446.57 120
PY2024 $2,987.57 117
PY2025 $2,927.92 166

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $90,123.43 88
PY2024 Principal investigator $274,429.62 94
PY2023 Recipient $2,043.08 1
PY2023 Principal investigator $473,903.36 51
PY2022 Recipient $30,901.00 2
PY2022 Principal investigator $30,194.94 80
PY2021 Principal investigator $63,248.75 78
PY2020 Principal investigator $16,057.00 4
PY2019 Principal investigator $10,098.13 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $400.00 12/04/2025 Non-covered Recipient Entity
Elevate Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184302803
Principal investigator 1 Ipsen Innovation $141.75 11/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295795
Principal investigator 1 Ipsen Innovation $44.55 10/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295791
Principal investigator 1 Ipsen Innovation $100.00 10/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295793
Principal investigator 1 Ipsen Innovation $44.55 09/15/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295773
Principal investigator 1 Ipsen Innovation $44.55 09/15/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295775
Principal investigator 1 Ipsen Innovation $200.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295771
Principal investigator 1 Ipsen Innovation $60.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295777
Principal investigator 1 Ipsen Innovation $141.75 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295779
Principal investigator 1 Ipsen Innovation $44.55 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295781
Principal investigator 1 Ipsen Innovation $250.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295783
Principal investigator 1 Ipsen Innovation $180.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295785
Principal investigator 1 Ipsen Innovation $100.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295787
Principal investigator 1 Ipsen Innovation $150.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295789
Principal investigator 1 Ipsen Innovation $500.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295761
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295763
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295765
Principal investigator 1 Ipsen Innovation $1,600.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295767
Principal investigator 1 Ipsen Innovation $2,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295769
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295749
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295751
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295753
Principal investigator 1 Ipsen Innovation $1,879.20 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295755
Principal investigator 1 Ipsen Innovation $450.00 07/14/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295759
Principal investigator 1 Eli Lilly and Company $685.00 07/09/2025 Non-covered Recipient Entity
ASHEVILLE ARTHRITIS AND OSTEOPOROSIS CENTER
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876377
Principal investigator 1 Ipsen Innovation $350.00 07/07/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295757
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295707
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295709
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295717
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295719
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295721
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295731
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295733
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295735
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295739
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295741
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295743
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295745
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295705
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295711
Principal investigator 1 Ipsen Innovation $100.24 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295713
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295723
Principal investigator 1 Ipsen Innovation $100.24 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295725
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295737
Principal investigator 1 Ipsen Innovation $2,149.20 06/20/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295729
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295715
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295727
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295747
Principal investigator 1 Ipsen Innovation $44.55 05/21/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295703
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295663
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295665
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295667
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295669
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295671
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295673
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295677
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295679
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295681
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295683
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295685
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295687
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295691
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295693
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295695
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295699
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295701
Principal investigator 1 Ipsen Innovation $90.00 04/22/2025 Non-covered Recipient Entity
Asheville Neurology Specialists, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287874
Principal investigator 1 Ipsen Innovation $150.00 04/22/2025 Non-covered Recipient Entity
Asheville Neurology Specialists, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287876
Principal investigator 1 Ipsen Innovation $360.00 04/14/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295675
Principal investigator 1 Ipsen Innovation $44.55 04/04/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295689
Principal investigator 1 Ipsen Innovation $390.25 04/04/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295697
Principal investigator 1 Ipsen Innovation $720.00 03/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295661
Principal investigator 1 Eli Lilly and Company $25,952.00 02/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187879225
Principal investigator 1 Ipsen Innovation $1,784.70 01/31/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295643
Principal investigator 1 Ipsen Innovation $500.00 01/29/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295631
Principal investigator 1 Ipsen Innovation $1,107.00 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295637
Principal investigator 1 Ipsen Innovation $1,107.00 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295641
Principal investigator 1 Ipsen Innovation $2,149.20 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295659
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295633
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295635
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295639
Principal investigator 1 Ipsen Innovation $500.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295645
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295647
Principal investigator 1 Ipsen Innovation $500.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295649
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295651
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295653
Principal investigator 1 Ipsen Innovation $1,000.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295655
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295657